Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2022-04-29 Governance Information
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司募集资金使用管理制度（2022年修订）
Governance Information Classification · 95% confidence The document is titled '募集资金使用管理制度' which translates to 'Fundraising Capital Usage Management System' and details the rules and procedures for managing and using funds raised by the company. It references relevant laws and regulations, outlines the management, storage, usage, changes, and supervision of raised funds, and includes responsibilities of the board, auditors, and independent directors. The document is a policy or internal management system rather than a financial report, announcement, or regulatory filing. It does not contain financial statements, earnings data, voting results, or other report types. It is a governance-related document focused on internal rules and procedures for capital management. Therefore, the most appropriate classification is Governance Information (CGR).
2022-04-29 Chinese
奥锐特药业股份有限公司独立董事工作细则（2022年修订）
Governance Information Classification · 95% confidence The document is titled '独立董事工作细则' which translates to 'Independent Director Work Rules'. It details the duties, qualifications, nomination, election, and responsibilities of independent directors within the company. The content focuses on governance structure, director obligations, and internal company rules rather than financial data, earnings, or regulatory filings. There is no indication that this is a report of financial results, audit, or a regulatory announcement. It is a governance-related document outlining internal rules and practices for independent directors. Therefore, it fits best under the category of Governance Information (CGR). The document length (6830 characters) and detailed content support this classification with high confidence.
2022-04-29 Chinese
奥锐特药业股份有限公司内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified accounting firm and addresses the effectiveness of internal controls over financial reporting for the fiscal year ending December 31, 2021. The content includes auditor responsibilities, company responsibilities, and an audit opinion on internal control effectiveness. The document is a standalone audit report focused on internal control over financial reporting, not a full annual report or other type of filing. The length is 1469 characters, which is short but contains substantive audit content, not merely an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2021
2022-04-29 Chinese
奥锐特药业股份有限公司关于修订公司部分治理制度的公告
Governance Information Classification · 95% confidence The document is an announcement regarding revisions to the company's governance systems and internal rules, including board and shareholder meeting procedures, management rules, and other governance-related policies. It details the approval process and the specific governance documents being added, revised, or abolished. There is no financial data, earnings information, or report publication mentioned. The focus is clearly on governance structure and internal rules. Therefore, the document fits the category of Governance Information (CGR). The document length is short and it is not merely announcing a report publication but providing substantive governance updates.
2022-04-29 Chinese
奥锐特药业股份有限公司关于公司及子公司向银行及其他融资机构申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company's board regarding the application for a comprehensive credit facility (授信额度) from banks and other financing institutions. It details the approval of a credit limit, its purpose, and authorization for company representatives to handle related matters. There is no financial statement, earnings data, or detailed report content. The document is short (709 characters) and serves as a formal announcement of financing activity rather than a full financial report or detailed presentation. Therefore, it fits best under Capital/Financing Update (CAP).
2022-04-29 Chinese
奥锐特药业股份有限公司独立董事关于续聘公司2022年度审计机构的事前认可意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the reappointment of the company's 2022 audit firm. It references the company's articles, relevant laws, and the qualifications and performance of the audit firm. The document does not contain financial statements or audit results but is an approval or endorsement related to audit services. It is not the audit report itself but a governance-related statement about audit firm reappointment. Therefore, it fits best under Audit Report / Information (AR), which includes applied accounting principles and audit-related information excluding full annual reports. FY 2022
2022-04-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.